{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:12:08Z","timestamp":1789708328119,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Intravenous immunoglobulin (IVIG) is a therapeutic intervention utilized in various disorders due to its antimicrobial, antiinflammatory, and immunomodulatory properties. The market offers a range of IVIG products, leading to variations in efficacy and safety profiles. This study aimed to systematically evaluate the safety profile of IVIG administration in pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic search was conducted on PubMed, Embase, and Cochrane databases using predetermined MeSH terms, covering the period from January 1, 2000, to October 15, 2022. Two independent reviewers performed relevance screening. Inclusion criteria encompassed English-language studies involving patients below 18 years of age who received IVIG treatment. Included studies were limited to peer-reviewed full-text publications with a minimum of 5 patients. A total of 8 studies met the inclusion criteria, encompassing 1088 pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight studies met the inclusion criteria (total 1088 pediatric patients). Five studies reported patient-level adverse event data suitable for pooling (688 patients). Among these 688 patients, 267 (38.8%) experienced adverse events (AEs). Among reported AEs, the most frequent were headache 68\/267 (25.5%) and fever 47\/267 (17.6%). Less common AEs included nausea 12\/267 (4.5%) and fatigue 12\/267 (4.5%). Four studies recorded a total of 2960 IVIG infusions, with 12.6% of infusions accompanied by AEs. The predominant AEs during infusions were headache (54.3%) and fever (29.4%). Cough (0.8%) and nausea (1.6%) were the least commonly observed AEs. Other AEs such as rash, vomiting, and abdominal pain were also reported. Of the 23 full-text articles reviewed, 8 were included. The remaining 15 were excluded due to the following reasons: 6 for duplicate data, 4 for inappropriate study design, 3 for not meeting the minimum number of patients, and 2 for incomplete adverse event reporting. These reasons are now detailed in the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IVIG therapy demonstrates good tolerability in pediatric patients, with an overall favorable safety profile, aside from mild AEs associated with its administration. Serious AEs were infrequent and mainly observed in high-risk patients. Headache was the most prevalent AE, which seldom required hospitalization and could be effectively managed with acetaminophen. Other AEs were generally mild systemic reactions. Notably, AEs appear to be more frequent during the initial exposure to IVIG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048173","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:02:07Z","timestamp":1776434527000},"page":"e48173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Safety assessment of intravenous immunoglobulins in pediatric population: A systematic review of adverse events"],"prefix":"10.1097","volume":"105","author":[{"given":"Muteb","family":"Altowairqi","sequence":"first","affiliation":[{"name":"Pediatric Department, AlHada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia"},{"name":"Pediatric Department, National Guard Hospital, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa M.","family":"Kamal","sequence":"additional","affiliation":[{"name":"Pediatric Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Aljaber","sequence":"additional","affiliation":[{"name":"Pediatric Department, National Guard Hospital, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Alelyani","sequence":"additional","affiliation":[{"name":"Pediatric Department, AlHada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen A.","family":"Alzaedi","sequence":"additional","affiliation":[{"name":"Pediatric Department, AlHada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.S.","family":"Aljuaid","sequence":"additional","affiliation":[{"name":"Pediatric Department, AlHada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah S.","family":"Algethami","sequence":"additional","affiliation":[{"name":"Pediatric Department, AlHada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.M.","family":"Oshi","sequence":"additional","affiliation":[{"name":"Gaafar Ibnauf Specialized Hospital, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.A.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Pediatric Department, Faculty of Medicine, Benha University, Banha, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1067\/mjd.2001.112325","article-title":"High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.","volume":"44","author":"R\u00fctter","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","article-title":"Clinical uses of intravenous immunoglobulin.","volume":"142","author":"Jolles","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations.","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"R4-20260605","first-page":"1","article-title":"Intravenous IgG: biological modulating molecules.","volume":"23","author":"Luzi","year":"2009","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4 Suppl","key":"R5-20260605","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3810\/pgm.2010.03.2131","article-title":"Case report: acute renal failure after administering intravenous immunoglobulin.","volume":"122","author":"Graumann","year":"2010","journal-title":"Postgrad Med"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R9-20260605","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.","volume":"49","author":"Kaba","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/trf.14301","article-title":"A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1\u201318 years with immune thrombocytopenia.","volume":"57","author":"Elalfy","year":"2017","journal-title":"Transfusion"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.aller.2020.05.008","article-title":"Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunoglobulin replacement.","volume":"48","author":"Ibis","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"108826","DOI":"10.1016\/j.clim.2021.108826","article-title":"Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.","volume":"230","author":"Esmaeilzadeh","year":"2021","journal-title":"Clin Immunol"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"2042098619876736","DOI":"10.1177\/2042098619876736","article-title":"Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study.","volume":"10","author":"Elajez","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"e0227796","DOI":"10.1371\/journal.pone.0227796","article-title":"Predictive factors of first\u2011dose intravenous immunoglobulin\u2011related adverse effects in children.","volume":"15","author":"Kubota","year":"2020","journal-title":"PLoS One"},{"key":"R17-20260605","first-page":"806","article-title":"Safety and efficacy of intravenous immunoglobulin in children.","volume":"14","author":"Ballow","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency.","volume":"26","author":"Church","year":"2006","journal-title":"J Clin Immunol"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/imt-2018-0074","article-title":"Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.","volume":"10","author":"Ochs","year":"2018","journal-title":"Immunotherapy"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10875-017-0424-4","article-title":"Efficacy and safety of human intravenous immunoglobulin 10% (Panzyga\u00ae) in patients with primary immunodeficiency diseases: a two-stage, multicenter, prospective, open-label study.","volume":"37","author":"Borte","year":"2017","journal-title":"J Clin Immunol"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy.","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence.","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:00:57Z","timestamp":1780675257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048173","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2024-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}